Kasten Inc. (KAST)

[MBADude]

From the 2017 annual statement:

On March 3, 2017, a Kasten Merger Sub merged with and into the private company Thru Pharma, LLC, d/b/a DAKOTA Life Sciences (“DAKOTA”), with the Merger Sub as the surviving corporation. The LLC Member Interests of DAKOTA were converted into the Merger Consideration comprising 42,000,000 shares of Kasten common stock.

NOW there doesn’t seem to be a single good thing that came off this. The company had the CE tagged for a while and didn’t file a single financial report after the merger. Arguably no value was added.

If Caren moves to have these 42 million shares canceled it might get granted. That’s huge for common shareholders and would make a reverse merger possible.

I can’t believe no one is discussing this here!